One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug.
Early diagnosis through blood tests buys invaluable time – for patients and their families to plan, seek support, make informed decisions about their difficult care journey and, perhaps most importantly, be together.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The vast majority of older adults want to age at home. To support that goal, doctors should encourage them to consider their care options — long before they need assistance.
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.
Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing.
The EMA’s Committee for Medicinal Products for Human Use expressed concern about brain complications associated with the Eisai Alzheimer’s drug, Leqembi. Eisai said it will ask the committee to reconsider the negative opinion.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative disorders.
Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy.
Takeda Pharmaceutical has secured an option on an Alzheimer’s disease immunotherapy from AC Immune that is on track to report its first Phase 2 data later this quarter. Exercising the option would make Takeda responsible for Phase 3 testing of the therapy, putting AC Immune in line for up to $2.1 billion in milestone payments.
Many women going through menopause suffer brain fog, but some may be worried about a more serious cognitive condition like dementia. Because of this, Midi Health and Neurotrack partnered to offer a cognitive assessment to patients.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Sanofi, which is leading development of the Denali Therapeutics-partnered molecule, disclosed little about the clinical trial results in ALS. But this Phase 2 failure follows the 2020 clinical trial pause of a different partnered molecule that addresses the same target.
Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.
Medical science has made significant strides in the development of advanced treatments over the past decade. However, the majority of FDA-approved treatments for Alzheimer’s focus on the management of symptoms or delayed progression of the disease.
The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.
We may not fully understand the link between Covid-19 and Alzheimer’s, but we already have the scientific research and tools to address people’s fears, support their cognitive health journey, and reverse the increase of Alzheimer’s.